# Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

> **NCT04499573** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 50 (estimated)

## Conditions studied

- B-ALL

## Interventions

- **DRUG:** CD19/CD22 CAR-T

## Key facts

- **NCT ID:** NCT04499573
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-27
- **Primary completion:** 2022-03-13
- **Final completion:** 2027-03-13
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04499573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04499573, "Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04499573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*